In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Growth Interrupted: Sustaining The Israeli Life Science Innovation Engine

Executive Summary

Maximizing the productivity of life science innovation hubs across the globe is of ever increasing importance to the continued vitality of the life science products industry. Israel's culture of innovation has produced a large number of start-up companies and product ideas, particularly in medical devices, but Israel has developed remarkably few mature life science companies. One major historical factor preventing Israeli start-ups from maturing into later stage companies is the absence of significant growth capital necessary to finance this kind of company development, which has lead to what the authors term an ongoing market failure. The authors argue that both private and public action is necessary to address this market failure in Israel, and that such action will benefit both that country and the industry as a whole by maintaining this fertile source of life science innovation.

You may also be interested in...

WHO To Clean Up Data Integrity Failings

The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date. 

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

Warning Letter Roundup & Recap – 10 December 2019

No device-related warning letters were released by the US FDA the week of 10 December.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts